B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal antibody, selectively targets and depletes CD20+ B lymphocytes.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): N Engl J Med

Title: The New England journal of medicine

Publisher: Massachusetts Medical Society

ISSN (Electronic): 1533-4406

ISSN (Print): 0028-4793

Publication date (Electronic): Feb 14 2008

Volume: 358

Issue: 7

Affiliations

[1 ] Department of Neurology, University of California at San Francisco, San Francisco, CA 94143-0114, USA. hausers@neurology.ucsf.edu

Article

Publisher Item ID: 358/7/676

DOI: 10.1056/NEJMoa0706383

PubMed ID: 18272891

SO-VID: 814e410f-c22e-47fd-afb6-91082c0fcc33

History

Data availability:

Comments

Comment on this article

scite_

Cited by 687

See all cited by

- Version 1